The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer

[1] Antoniou AC(2007)RAD51 135G>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies Am J Hum Genet 81 1186-1200

[2] Sinilnikova OM(2005)Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Lancet 366 2087-2106

[3] Simard J(2007)DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population Breast Cancer Res Treat 103 209-217

[4] Clarke M(2010)A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer Clin Cancer Res 16 6159-6168

[5] Collins R(2007)Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation Mol Cancer Ther 6 1650-1660

[6] Darby S(2003)The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer Int J Cancer 105 472-479

[7] Costa S(2005)Characterisation of the promoter region of the human DNA-repair gene Rad51 Eur J Gynaecol Oncol 26 589-598

[8] Pinto D(2003)Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance Toxicology 193 91-109

[9] Pereira D(2014)A small inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts PLoS One 9 e100993-69

[10] Graeser M(2007)RAD51 135G>C polymorphism and risk of familial breast cancer in a South American population Cancer Genet Cytogenet 178 65-2005

[1] Antoniou AC(2007)RAD51 135G>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies Am J Hum Genet 81 1186-1200

[2] Sinilnikova OM(2005)Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Lancet 366 2087-2106

[3] Simard J(2007)DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population Breast Cancer Res Treat 103 209-217

[4] Clarke M(2010)A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer Clin Cancer Res 16 6159-6168

[5] Collins R(2007)Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation Mol Cancer Ther 6 1650-1660

[6] Darby S(2003)The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer Int J Cancer 105 472-479

[7] Costa S(2005)Characterisation of the promoter region of the human DNA-repair gene Rad51 Eur J Gynaecol Oncol 26 589-598

[8] Pinto D(2003)Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance Toxicology 193 91-109

[9] Pereira D(2014)A small inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts PLoS One 9 e100993-69

[10] Graeser M(2007)RAD51 135G>C polymorphism and risk of familial breast cancer in a South American population Cancer Genet Cytogenet 178 65-2005